Help us make pertuzumab (Perjeta) for secondary breast cancer available in Scotland
We need your help. The Scottish Medicines Consortium (SMC) are assessing whether or not to recommend pertuzumab (Perjeta) to be available on the NHS in Scotland. Pertuzumab for treating HER2 positive secondary breast cancer is available on the NHS to women who live in England, Wales and Northern Ireland, but it's not currently available in Scotland.
We are gathering evidence to tell the SMC what access to pertuzumab would mean and want to hear from: womenwho have been or are being treated withpertuzumab for secondary breast cancerin England, Wales and Northern Ireland, or women in Scotland who haveHER2 positive secondary breast cancer.